CR9112A - Formas de dosificacion oral solidas que contienen una dosis baja de estradiol - Google Patents

Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Info

Publication number
CR9112A
CR9112A CR9112A CR9112A CR9112A CR 9112 A CR9112 A CR 9112A CR 9112 A CR9112 A CR 9112A CR 9112 A CR9112 A CR 9112A CR 9112 A CR9112 A CR 9112A
Authority
CR
Costa Rica
Prior art keywords
dosage forms
estradiol
solid oral
oral dosage
forms containing
Prior art date
Application number
CR9112A
Other languages
English (en)
Inventor
Funke Adrian
Muller Kristina
Wagner Torsten
Zurth Christian
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9112A publication Critical patent/CR9112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion se refiere a formas de dosificacion oral solidas que contienen una dosis muy baja de estradiol. Las formas de dosificacion se formulan de modo tal que se evita la degradacion del estradiol y se minimiza el contenido de polivinilpirrolidona, al tiempo que aun se logra una disolucion rapida similar a la del estradiol. Las formas de dosificacion son utiles para prevenir o tratar una condicion fisica provocada en una mujer por niveles endogenos insuficientes de estradiol.
CR9112A 2004-11-02 2007-05-09 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol CR9112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
CR9112A true CR9112A (es) 2007-11-23

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9112A CR9112A (es) 2004-11-02 2007-05-09 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Country Status (21)

Country Link
EP (1) EP1814526A2 (es)
JP (1) JP2008518895A (es)
KR (1) KR20070085558A (es)
CN (1) CN101094656A (es)
AR (1) AR053650A1 (es)
AU (1) AU2005300658A1 (es)
BR (1) BRPI0517940A (es)
CA (1) CA2585095A1 (es)
CR (1) CR9112A (es)
CU (1) CU20070094A7 (es)
EA (1) EA013262B1 (es)
GT (1) GT200500315A (es)
IL (1) IL182635A0 (es)
MX (1) MX2007005281A (es)
NO (1) NO20072704L (es)
PA (1) PA8651401A1 (es)
PE (1) PE20061126A1 (es)
TW (1) TW200621312A (es)
UY (1) UY29185A1 (es)
WO (1) WO2006048261A2 (es)
ZA (1) ZA200705012B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047957A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 고혈압의 치료 및 예방을 위한 약제 조성물
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP2558076B1 (en) 2010-04-15 2014-12-24 Bayer Intellectual Property GmbH Low-dosed solid oral dosage forms for hrt
MX356702B (es) * 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
CN112516149B (zh) * 2020-07-21 2023-07-18 南方医科大学 苯甲酸雌二醇或其药物可接受盐在制备抗冠状病毒的药物中的应用
JP2024000555A (ja) * 2022-06-21 2024-01-09 東ソー株式会社 紫外線抑制下でのエストラジオール測定試薬の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125069C (es) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
JP2004512369A (ja) * 2000-10-30 2004-04-22 ユニバーシティ・オブ・チューリッヒ 尿失禁の治療のためのｇｎｒｈアナログ
DK1343508T3 (da) * 2000-12-15 2012-02-27 Novo Nordisk Femcare Ag Anvendelse af et østrogen til fremstilling af en sammensætning, der indeholder østrogen, til behandling af atrofisk vaginitis
FR2823976A1 (fr) * 2001-04-25 2002-10-31 Theramex Nouvelle composition hormonale et son utilisation
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (ja) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 更年期症の予防・治療用経口組成物

Also Published As

Publication number Publication date
EA200700979A1 (ru) 2007-10-26
PE20061126A1 (es) 2006-11-11
CN101094656A (zh) 2007-12-26
JP2008518895A (ja) 2008-06-05
ZA200705012B (en) 2008-10-29
KR20070085558A (ko) 2007-08-27
PA8651401A1 (es) 2006-12-07
NO20072704L (no) 2007-05-29
WO2006048261A3 (en) 2006-09-21
UY29185A1 (es) 2006-05-31
IL182635A0 (en) 2007-07-24
TW200621312A (en) 2006-07-01
AR053650A1 (es) 2007-05-16
WO2006048261A2 (en) 2006-05-11
GT200500315A (es) 2006-06-06
CA2585095A1 (en) 2006-05-11
BRPI0517940A (pt) 2008-10-21
EP1814526A2 (en) 2007-08-08
CU20070094A7 (es) 2009-09-08
EA013262B1 (ru) 2010-04-30
MX2007005281A (es) 2008-03-11
AU2005300658A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CR9112A (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
AR109263A2 (es) Composición que comprende moxidectina
CR9662A (es) Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
BRPI0414428A (pt) composições farmacêuticas
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
MX2007006104A (es) Metodos para purificar trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol.
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
PL375621A1 (pl) Kompozycje farmaceutyczne zawierające flawonoidy i mentol
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
AR127158A1 (es) Oligonucléotido antisentido para la edición de arn asociado a enfermedades de poliglutamina
MXPA06012566A (es) Tratamiento de enfermedades infecciosas.
AR039977A1 (es) Composicion a base de diclofenac para el tratamiento topico de afecciones de la cavidad orofaringea
GT200900295A (es) Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias.
AR048355A1 (es) Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)